SUMO4: A Potential Drug Target and Biomarker for Multiple Chronic Diseases

Target Name: SUMO4

NCBI ID: G387082

SUMO4

SUMO4: A Potential Drug Target and Biomarker for Multiple Chronic Diseases

SUMO4, or small ubiquitin-like modifier 4, is a protein that plays a crucial role in cellular signaling pathways. As a post-translational modification (PTM) protein, SUMO4 modifies the stability and localization of other proteins, leading to a wide range of physiological processes. SUMO4 has been implicated in numerous diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, targeting SUMO4 has the potential to develop new treatments for a variety of chronic diseases.

SUMO4 functions as a negative regulator of the ubiquitin system, which is a protein degradation pathway that is critical for maintaining cellular homeostasis and cell signaling. In ubiquitin-proteasome system (UPS), SUMO4 helps to regulate the assembly and disassembly of ubiquitin chains. SUMO4 can interact with several ubiquitin proteins, including alpha-2 (UCS1), alpha-3 (UCS2), and alpha-6 (UCS3), to modulate their stability and localization.

SUMO4 has been shown to play a key role in a variety of cellular processes, including cell signaling, cell division, and DNA damage repair. In cancer cells, SUMO4 is often overexpressed or mutated, leading to the development of a range of negative signaling pathways. For example, SUMO4 has been implicated in the regulation of cell adhesion, migration, and invasion. In addition, SUMO4 has been linked to the regulation of cell proliferation, apoptosis, and angiogenesis.

SUMO4 has also been shown to play a role in neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. SUMO4 has been shown to interact with the neurotransmitter dopamine and to regulate the levels of dopamine in brain cells. SUMO4 may also be involved in the regulation of neuroinflammation, which is a key aspect of the development of neurodegenerative diseases.

In addition to its role in cellular signaling, SUMO4 has also been implicated in the regulation of protein stability and localization. SUMO4 can interact with other proteins to modulate their stability and localization, including the protein LAT, which is involved in the regulation of mitochondrial dynamics. SUMO4 has also been shown to interact with the protein NEDD8, which is involved in the regulation of protein stability and localization in the endoplasmic reticulum.

SUMO4 has also been shown to play a role in autoimmune diseases, including rheumatoid arthritis and multiple sclerosis. SUMO4 has been shown to interact with the immune protein IFN-gamma, and to regulate the production of autoantibodies. SUMO4 may also be involved in the regulation of inflammation and the immune response.

In conclusion, SUMO4 is a protein that has a wide range of physiological functions and has been implicated in a variety of chronic diseases. The potential drug targets for SUMO4 include the regulation of cellular signaling, protein stability and localization, and inflammation. Further research is needed to fully understand the role of SUMO4 in these processes and to develop effective treatments for chronic diseases.

Protein Name: Small Ubiquitin Like Modifier 4

Functions: Ubiquitin-like protein which can be covalently attached to target lysines as a monomer. Does not seem to be involved in protein degradation and may modulate protein subcellular localization, stability or activity. Upon oxidative stress, conjugates to various anti-oxidant enzymes, chaperones, and stress defense proteins. May also conjugate to NFKBIA, TFAP2A and FOS, negatively regulating their transcriptional activity, and to NR3C1, positively regulating its transcriptional activity. Covalent attachment to its substrates requires prior activation by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I

The "SUMO4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SUMO4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets